Treatment and prevention of sudden cardiac death: Effect of recent clinical trials

Archives of Internal Medicine

Volumn 159, Issue 12, 1999, Pages 1281-1287

  Goldberger, Jeffrey J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; ELECTROCARDIOGRAM; HEART EJECTION FRACTION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HUMANS; RECURRENCE; RISK; TACHYCARDIA, VENTRICULAR;

EID: 0033612548     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.12.1281     Document Type: Review

References (41)

1. Baum RS, Alvarez H III, Cobb LA. Survival after resuscitation from out-of-hospital ventricular fibrillation. Circulation. 1974;50:1231-1235.
2. Cobb LA, Baum RS, Alvarez H III, Schaffer WA. Resuscitation from out-of-hospital ventricular fibrillation: 4 years' follow-up. Circulation. 1975; 52(suppl):111223-111235.
3. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation. 1996; 93:519-524.
4. Epstein A, Carlson M, Fogoros R, Higgins S, Venditti F. Classification of death in antiarrhythmia trials. J Am Coll Cardiol. 1996;27: 433-442.
5. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med. 1992;327: 987-992.
6. Wiesfeld AC, Crijns HJ, Hillege HL, Tuininga YS, Lie KL. The clinical significance of coronary anatomy in post-infarct patients with late sustained ventricular tachycardia or ventricular fibrillation. Eur Heart J. 1995;16:818-824.
7. Lessmeier TJ, Lehmann MH, Steinman RT, et al. Implantable cardioverter-defibrillator therapy in 300 patients with coronary artery disease presenting exclusively with ventricular fibrillation. Am Heart J. 1994;128:211-218.
8. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13: 442-449.
9. Antiarrhythmics Versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
10. Myers M, Peter T, Weiss D, et al. Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. Am Heart J. 1990;119:8-14.
11. Mason JW. A comparison of electrophysiologic testing with Holler monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias: Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329:445-451.
12. Mitchell LB, Sheldon RS, Gillis AM, et al. Definition of predicted effective antiarrhythmic drug therapy for ventricular tachyarrhythmias by the electrophysiologic study approach: randomized comparison of patient response criteria. J Am Coll Cardiol. 1997;30:1346-1353.
13. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med. 1988;318:19-24.
14. Bocker D, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. Comparison of D,L-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation. 1996;94:151-157.
15. Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of D,L-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol. 1997;30:487-495.
16. Zipes D, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. Circulation. 1995;92:59-65.
17. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias: Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329:452-458.
18. Reiffel JA, Reiter MJ, Freedman RA, et al. Influence of Holler monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Prog Cardiovasc Dis. 1996;38:359-370.
19. Mitchell LB, Duff HJ, Manyari DE, Wyse DG. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med. 1987;317:1681-1687.
20. Horowitz LN, Greenspan AM, Spielman SR, et al. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol. 1985;55:367-371.
21. Weinberg BA, Miles WM, Klein LS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J. 1993;125:109-120.
22. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators [published corrections appeared in Lancet. 1997;349:1180; 1776]. Lancet. 1997;349:667-674.
23. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published correction appears in Lancet. 1997;349:1776]. Lancet 1997;349:675-682.
24. Connolly SJ, Cairns JA, Gent M, Roberts R, Yusuf S. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997; 350:1417-1424.
25. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195-2203.
26. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-336.
27. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results. Circulation. 1993;87:312-322.
28. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Lancet. 1994;344: 493-498.
29. Cardiac Arrhythmia Suppression Trial Investigators (CAST). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
30. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270:1589-1595.
31. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334:1349-1355.
32. Waldo AL, Camm AJ, deRuyter H, et al. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: The SWORD Investigators: Survival With Oral D-Sotalol [published correction appears in Lancet. 1996;348:416]. Lancet. 1996; 348:7-12.
33. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation. 1990;82:350-358.
34. Gomes JA, Hariman RI, Kang PS, El-Sherif N, Chowdhry I, Lyons J. Programmed electrical stimulation in patients with high-grade ventricular ectopy: electrophysiologic findings and prognosis for survival. Circulation. 1984;70:43-51.
35. Buxton AE, Marchlinski FE, Flores BT, Miller JM, Doherty JV, Josephson ME. Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. Circulation. 1987;75:1178-1185.
36. Klein RC, Machell C. Use of electrophysiologic testing in patients with nonsustained ventricular tachycardia: prognostic and therapeutic implications. J Am Coll Cardiol. 1989;14:155-161.
37. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-1940.
38. Bigger JT Jr, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997; 337:1569-1575.
39. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT: Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97:2129-2135.
40. Kupersmith J, Hogan A, Guerrero P, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J. 1995;130(pt 1):507-515.
41. Wever EF, Hauer RN, Schrijvers G, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: a randomized study. Circulation. 1996; 93:489-496.